RICARDO
RUIZ VILLAVERDE
Centro Medico Teknon
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Centro Medico Teknon (3)
2022
-
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study
F1000Research, Vol. 11
-
Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis
Dermatologic Therapy, Vol. 35, Núm. 10
-
Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab
Dermatologic Therapy, Vol. 35, Núm. 11